secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-TECHNE Corp (TECH)
CIK:        0000842023
Form:       8-K
Filed at:   2024-04-30T23:59:59+00:00
Accession:  0001558370-24-006279
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Techne appoints Dr. Judith Klimovsky to board, expands to 11 directors
--------------------------------------------------------------------------

- Dr. Klimovsky appointed independent director effective April 24, 2024; board temporarily expanded to 11 members (10 independent).
- She will serve on the Science & Technology Committee.
- Dr. Klimovsky is EVP & Chief Development Officer at Genmab; previously held senior roles at Novartis Oncology and Bristol-Myers Squibb.
- Board also approved a one-year waiver of mandatory retirement policy for Dr. Roeland Nusse.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/842023/000155837024006279/0001558370-24-006279-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/842023/000155837024006279/tmb-20240424x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-006279

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer